ASCL1 and small cell lung carcinoma: Somatic mutation and transcriptional upregulation of the WNT pathway are associated with chemorefractoriness in SCLC.[23] By integrated analysis, we provided evidence that high expression of FZD8 in WNT pathway was correlated with drug resistance in SCLC malignant cells.[30] Second, ASCL1 and NEUROD1 were indeed the most common markers in the malignant cells from the SCLC patients.